Mapping dopaminergic function using pharmacologic Magnetic Resonance Imaging (phMRI) in healthy subjects and users of amphetamine

• Conditions: drugsgebruik/verslaving; brain damage; neurotoxicity; 10029305

• Registration Number: NL-OMON33348
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Male. Between 18 and 35 years of age. Regular use of amphetamines (on more than 40 occasions the past year) for the amphetamine using group

Exclusion Criteria

Serious general medical condition or one that could interfere in the interpretation of results
-use of (DA) medication within the last 2 weeks
-excessive consumption of alcohol (>21 units/ week), caffeine (greater than eight cups of coffee per day) or cigarettes (greater than ten cigarettes per day).
-Contraindications for MRI (e.g. osteosynthetic material, pacemaker, artificial cardiac valves), claustrophobia

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Task related MRI: task related % change in BOLD and ASL signals.<br /><br>Task related phMRI: % change in BOLD and ASL signal after an oral<br /><br>methylphenidate challenge in task activated regions.<br /><br>Steady state phMRI: % change in BOLD and ASL signal from baseline after an<br /><br>oral methylphenidate challenge.<br /><br>SPECT: DAT ratio (striatal ROI binding/binding in cerebellum).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>MRS: N-acetylasparate (NAA)/Creatine (Cr) ratio.<br /><br>DTI: fractional anisotropy (FA). </p><br>